BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11296138)

  • 1. Positron emission tomography and gallium metabolic imaging in lymphoma.
    Coiffier B
    Curr Oncol Rep; 2001 May; 3(3):266-70. PubMed ID: 11296138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
    Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
    Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography.
    Kostakoglu L; Goldsmith SJ
    Clin Lymphoma; 2000 Jun; 1(1):67-74; discussion 75-6. PubMed ID: 11707816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of FDG-PET imaging in the management of lymphoma.
    Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?
    Kostakoglu L; Goldsmith SJ
    Eur J Nucl Med; 2000 Oct; 27(10):1564-78. PubMed ID: 11083548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography in the evaluation of lymphoma.
    Israel O; Keidar Z; Bar-Shalom R
    Semin Nucl Med; 2004 Jul; 34(3):166-79. PubMed ID: 15202099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan.
    Hong SP; Hahn JS; Lee JD; Bae SW; Youn MJ
    Yonsei Med J; 2003 Oct; 44(5):779-86. PubMed ID: 14584092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
    Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
    Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging: staging and evaluation of lymphoma using nuclear medicine.
    Divgi C
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S11-8. PubMed ID: 15786021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorine-18-fluorodeoxyglucose positron emission tomography metabolic imaging in patients with lymphoma.
    Huić D; Dodig D
    Croat Med J; 2002 Oct; 43(5):541-5. PubMed ID: 12402392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET scans in the staging of lymphoma: current status.
    Friedberg JW; Chengazi V
    Oncologist; 2003; 8(5):438-47. PubMed ID: 14530496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of FDG-PET in malignant lymphoma.
    Becherer A; Jaeger U; Szabo M; Kletter K
    Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography imaging for lymphoma.
    Jerusalem G; Hustinx R; Beguin Y; Fillet G
    Curr Opin Oncol; 2005 Sep; 17(5):441-5. PubMed ID: 16093792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Malignant lymphoma].
    Okamoto R
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2532-6. PubMed ID: 20009452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underperformance of gallium-67 scan is greater in relapse than in initial staging, compared with FDG PET.
    Huang YY; You DL; Liu MC; Tan TD; Lee PI; Lee MY
    Clin Nucl Med; 2011 Oct; 36(10):867-71. PubMed ID: 21892035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients.
    Van Den Bossche B; Lambert B; De Winter F; Kolindou A; Dierckx RA; Noens L; Van De Wiele C
    Nucl Med Commun; 2002 Nov; 23(11):1079-83. PubMed ID: 12411836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment.
    Bar-Shalom R; Mor M; Yefremov N; Goldsmith SJ
    Semin Nucl Med; 2001 Jul; 31(3):177-90. PubMed ID: 11430525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of 18F-fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma.
    Lin P; Chu J; Kneebone A; Moylan E; Jalaludin B; Pocock N; Kiat H; Rosenfeld D
    Intern Med J; 2005 Feb; 35(2):91-6. PubMed ID: 15705137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.